Equities Analysts Set Expectations for Biogen Q4 Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Wedbush cut their Q4 2024 earnings per share (EPS) estimates for shares of Biogen in a research report issued to clients and investors on Wednesday, October 30th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $3.29 for the quarter, down from their prior estimate of $3.58. Wedbush has a “Neutral” rating and a $205.00 price target on the stock. The consensus estimate for Biogen’s current full-year earnings is $16.40 per share. Wedbush also issued estimates for Biogen’s Q1 2025 earnings at $4.02 EPS, Q2 2025 earnings at $4.02 EPS, Q3 2025 earnings at $3.93 EPS, Q4 2025 earnings at $4.11 EPS, FY2025 earnings at $16.08 EPS and FY2026 earnings at $16.73 EPS.

Several other equities analysts have also recently weighed in on the company. Scotiabank lowered their target price on Biogen from $275.00 to $244.00 and set a “sector outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating in a research report on Monday, September 2nd. Wells Fargo & Company lowered their price target on shares of Biogen from $240.00 to $225.00 and set an “equal weight” rating on the stock in a report on Friday, August 2nd. Raymond James reiterated a “market perform” rating on shares of Biogen in a report on Thursday, October 10th. Finally, Oppenheimer lowered their target price on Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $261.58.

Biogen Stock Performance

Shares of BIIB stock opened at $176.93 on Monday. The stock’s fifty day simple moving average is $191.56 and its 200-day simple moving average is $209.34. The company has a market capitalization of $25.78 billion, a price-to-earnings ratio of 15.98, a P/E/G ratio of 1.65 and a beta of -0.06. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. Biogen has a 1-year low of $170.71 and a 1-year high of $268.30.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.43 billion. During the same quarter in the previous year, the business earned $4.36 earnings per share. The firm’s revenue was down 2.5% compared to the same quarter last year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 431 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $204.22, for a total value of $88,018.82. Following the completion of the sale, the insider now directly owns 5,316 shares of the company’s stock, valued at $1,085,633.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Institutional Trading of Biogen

A number of hedge funds have recently modified their holdings of the company. Norden Group LLC boosted its stake in Biogen by 25.2% during the first quarter. Norden Group LLC now owns 1,440 shares of the biotechnology company’s stock worth $311,000 after buying an additional 290 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Biogen by 4.9% during the first quarter. Private Advisor Group LLC now owns 4,833 shares of the biotechnology company’s stock valued at $1,042,000 after purchasing an additional 224 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Biogen by 15.8% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,408 shares of the biotechnology company’s stock valued at $735,000 after purchasing an additional 465 shares during the period. BNP Paribas bought a new position in shares of Biogen during the 1st quarter worth approximately $151,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of Biogen by 10.6% during the 1st quarter. Daiwa Securities Group Inc. now owns 22,651 shares of the biotechnology company’s stock worth $4,884,000 after buying an additional 2,172 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.